- Home
- BTBT vs GYRE Comparison
BTBT vs GYRE Comparison
Compare BTBT & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTBT
- GYRE
- Stock Information
- Founded
- BTBT 2015
- GYRE 2002
- Country
- BTBT United States
- GYRE United States
- Employees
- BTBT N/A
- GYRE N/A
- Industry
- BTBT Finance: Consumer Services
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- BTBT Finance
- GYRE Health Care
- Exchange
- BTBT Nasdaq
- GYRE Nasdaq
- Market Cap
- BTBT 1.1B
- GYRE 897.1M
- IPO Year
- BTBT 2018
- GYRE N/A
- Fundamental
- Price
- BTBT $2.58
- GYRE $7.74
- Analyst Decision
- BTBT Strong Buy
- GYRE Strong Buy
- Analyst Count
- BTBT 3
- GYRE 1
- Target Price
- BTBT $6.33
- GYRE $18.00
- AVG Volume (30 Days)
- BTBT 29.1M
- GYRE 85.6K
- Earning Date
- BTBT 08-14-2025
- GYRE 08-11-2025
- Dividend Yield
- BTBT N/A
- GYRE N/A
- EPS Growth
- BTBT N/A
- GYRE N/A
- EPS
- BTBT N/A
- GYRE 0.02
- Revenue
- BTBT $98,402,256.00
- GYRE $102,189,000.00
- Revenue This Year
- BTBT $16.34
- GYRE $21.04
- Revenue Next Year
- BTBT $44.80
- GYRE $89.64
- P/E Ratio
- BTBT N/A
- GYRE $455.91
- Revenue Growth
- BTBT 13.30
- GYRE N/A
- 52 Week Low
- BTBT $1.69
- GYRE $6.11
- 52 Week High
- BTBT $5.74
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- BTBT 38.85
- GYRE 49.96
- Support Level
- BTBT $2.60
- GYRE $7.61
- Resistance Level
- BTBT $2.91
- GYRE $8.40
- Average True Range (ATR)
- BTBT 0.16
- GYRE 0.53
- MACD
- BTBT -0.04
- GYRE 0.04
- Stochastic Oscillator
- BTBT 4.11
- GYRE 62.92
About BTBT Bit Digital Inc.
Bit Digital Inc is engaged in the Bitcoin mining business, Ethereum staking activities and specialized cloud-infrastructure services for artificial intelligence applications through its wholly owned subsidiaries. Its mining platform operates with the primary intent of accumulating bitcoin which may sell for fiat currency from time to time depending on market conditions. The Company has four reportable segments: digital asset mining, cloud services, colocation services, and ETH Staking. It generates majority of its revenue from digital asset mining.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.